Panelists discuss how treatment decisions in metastatic melanoma involve balancing the benefits of immunotherapy versus targeted therapy, taking into account factors such as tumor genetics, patient response, and tolerability.
Encorafenib Combo May Limit Recurrence Risk in BRAF V600+ Melanoma
Phase 3 data demonstrate the potential utility of BRAF/MEK inhibition in the adjuvant setting for patients with stage IIB/IIC BRAF V600–mutant melanoma.
OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma
John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.
RP1/Nivolumab Combo Shows Responses in Advanced Pretreated Melanoma
Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.
Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma
On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.
Nivolumab/Relatlimab Elicit IC Activity in Anti–PD-L1–Refractory Melanoma Brain Mets
The combination elicited a clinical benefit rate of 63.0% and an overall response rate of 22.2% in anti–PD-L1–refractory melanoma with melanoma brain metastases.
Relatlimab Shows Comparable Efficacy to Ipilimumab in Advanced Melanoma
Efficacy across most patient subgroups appeared to be consistent with relatlimab/nivolumab vs ipilimumab/nivolumab in patients with advanced melanoma.